The at-home delivery of treatment for benign prostate enlargement and chronic prostatitis enabled by Dr Allen’s Device is a valuable healthcare innovation during a pandemic
Abstract
Introduction: The Coronavirus (COVID-19) outbreak has demonstrated the need for a novel delivery of treatment for benign prostate enlargement (BPE) and chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS). Their standard treatments with medications and surgeries require extensive contact between patients and healthcare professionals that worsens a pandemic. This study aims to determine whether therapeutic Dr Allen’s Device (DATD) and Thermobalancing therapy (TT) can be used as an effective self-management tool and at-home treatment for chronic prostate diseases.
Methods: This is a retrospective cohort study of 45 men with CP/CPPS and 124 men with BPE who were observed before and after applying TT with DATD at home for 6 months in 2 clinical controlled trials. The dynamics of clinical characteristics and parameters, such as pain, urinary symptoms, quality of life (QoL), and prostate volume (PV) were compared to the control groups without DATD.
Results: DATD reduced pain scores from 10.3 to 3.5 (P<0.001) in men with CP/CPPS. In men with BPE, DATD reduced PV from 45mL to 31mL (P<0.001) and urinary symptoms from 14.3 to 4.9 (P<0.001). DADT significantly improved QoL in both treatment groups. In the control groups, no positive changes were observed.
Conclusions: The use of DATD with TT relieves chronic pelvic pain and reduces an abnormal prostate size in patients with CP/CPPS and BPE, improving their QoL and wellbeing. Thus, DATD is an effective at-home self-management tool and provides a novel delivery of treatment for non-cancerous prostatic diseases, especially important during a pandemic.
Downloads
References
World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Published March 11, 2020 (accessed March 20, 2020).
Li Q, Guan X, Wu P, Wang X et al. Early transmission dynamics in Wuhan, China, of novel coronavirus infected pneumonia. N Engl J Med 2020; 382:1199-1207. https://doi.org/10.1056/NEJMoa.2001316.
Ho HC, Hughes T, Bozlu M et al. What do urologists need to know: Diagnosis, treatment, and follow-up during COVID-19 pandemic. Turk J Urol. 2020 Apr 14. doi: 10.5152/tud.2020.20119.
Witherspoon L, Fitzpatrick R, Patel P, Flannigan R et al. Clinical pearls to managing men’s health conditions during the COVID-19 pandemic. Can Urol Assoc. 2020; 14(5): E161-6. doi: 10.5489/cuaj.6631.
Rohrmann S, Katzke V, Kaaks R. Prevalence and Progression of Lower Urinary Tract Symptoms in an Aging Population. Urology. 2016; 95:158-63. doi: 10.1016/j.urology.2016.06.021.
Magistro G, Wagenlehner FM, Grabe M, et al. Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome, Eur Urol. 2016 Feb;69(2):286-97. doi: 10.1016/j.eururo.2015.08.061.
Woodard TJ, Manigault KR, McBurrows NN et al. Management of Benign Prostatic Hyperplasia in Older Adults. Consult Pharm. 2016;31(8):412-24. doi: 10.4140/TCP.n.2016.412.
Dimitropoulos K, Gravas S. New therapeutic strategies for the treatment of male lower urinary tract symptoms. Res Rep Urol. 2016; 8:51-9. Published 2016 Apr 26. doi:10.2147/RRU.S63446
Norton JM, Bavendam TG, Elwood WN et al. Research needs to understand self-management in Men with LUTS: A review and summary of a NIDDK workshop. J Uro 2017; doi: 10.1016/j.juro.2017.11.079.
Giatti S, Diviccaro S, Panzica G, Melcangi RC. Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin? Endocrine. 2018 Aug;61(2):180-193. doi: 10.1007/s12020-018-1593-5.
Doiron RC, Nickel JC. Management of chronic prostatitis/chronic pelvic pain. syndrome. Can Urol Assoc J. 2018;12(6 Suppl 3): S161-S163.
Traish AM. The Post-Finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption, Curr Sex Health Rep (2018) 10: 88. https://doi.org/10.1007/s11930-018-0161-6
Allen S. Innovative Thermobalancing therapy using Dr. Allen's device for the first time employs the body energy to treat the chronic prostatic disease effectively, Int J Qual Innov, 2020, 6, 2. doi: 10.1186/s40887-020-00035-0.
Allen S, Adjani, A. Therapeutic Device and Method, United States Patent and Trademark Office. U.S. Patent 9,408,744 B2, 9 August 2016. Available online: https://www.google.com/patents/US9408744 (accessed June 11, 2021).
Allen S, Aghajanyan IG. Benign Prostatic Hyperplasia Treatment with New Physiotherapeutic Device, Urol J. 2015, 14;12(5):2371-2376.
Allen S, Aghajanyan IG. Effect of thermobalancing therapy on chronic prostatitis and chronic pelvic pain syndrome, Journal of Clinical Urology, 2016, Sept 20, 1-8. doi: 10.1177/2051415816671036.
Paital B, Das K, Parida SK. Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India [published online ahead of print, 2020 Apr 23]. Sci Total Environ. 2020; 728:138914. doi: 10.1016/j.scitotenv.2020.138914.
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507‐513. doi:10.1016/S0140-6736(20)30211-7.
Liu Y, Mao B, Liang S, et al. Association between ages and clinical characteristics and outcomes of coronavirus disease 2019 [published online ahead of print, 2020 Apr 27]. Eur Respir J. 2020;2001112. doi:10.1183/13993003.01112-2020.
Stensland KD, Morgan TM, Moinzadeh A, et al. Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic. Eur Urol. 2020; S0302-2838(20)30202-5. doi: 10.1016/j.eururo.2020.03.027.
Descazeaud A, Robert G, de La Taille A. [Sexual consequences of BPH treatments]. Progres en Urologie: Journal de L'association Francaise D'urologie et de la Societe Francaise D'urologie. 2018 Nov;28(15):839-847. doi: 10.1016/j.purol.2018.07.278.
Koren G. Retrograde Ejaculation — a Commonly unspoken aspect of prostatectomy for benign prostatic hypertrophy. American Journal of Men's Health, 2020, Volume: 14 issue: 2. doi.org/10.1177/1557988320910870.
Aghajanyan IG, Allen S. Positive Response to Thermobalancing Therapy Enabled by Therapeutic Device in Men with Non-Malignant Prostate Diseases: BPH and Chronic Prostatitis, Diseases 2016, 4, 18. doi:10.3390/diseases4020018.
Allen S. Dr. Allen’s Therapeutic Devices Should be Implemented in the Healthcare System for the Treatment of Chronic Noncancerous Prostate and Kidney Diseases Saving People’s Well-Being and Money, Ann Mil Health Sci Res. 2018; 16(2): e81033. doi: 10.5812/amh.81033.
Gandhi J, Weissbart SJ, Smith NL, et al. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Translational Andrology and Urology. 2017;6(2):295-304. doi:10.21037/tau.2017.03.57.
Bortnick, E., Simma-Chiang, V., Omidele, O, et al. Medical Therapies for Treatment of BPH: Special Considerations in Elderly Men, Curr Geri Rep. 2019, Nov. pp 1-5. https://doi.org/10.1007/s13670-019-00299-1
Kim JH, Shim SR, Khandwala Y et al. Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis. World J Men’s Health. 2019 Jan;37: e27, https://doi.org/10.5534/wjmh.190046.
Baron M, Cornu JN. Medical Aspects of the Treatment of LUTS/BPH: Alpha-Blockers. Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia, 2018, Chapter 8, Pages 177-188, https://doi.org/10.1016/B978-0-12-811397-4.00008-1.
Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020 Jan;113(1):21-50. doi: 10.1016/j.fertnstert.2019.11.030.
Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Coronavirus (COVID-19) [Updated 2020 Apr 6]. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/.
Paul L. Non-steroidal anti-inflammatory drugs and covid-19 BMJ 2020; 368:m1185. doi: https://doi.org/10.1136/bmj.m1185.
Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19, Journal of Travel Medicine, taaa041, https://doi.org/10.1093/jtm/taaa041
Adamowicz J, Juszczak K, Drewa T. May patients receiving 5-alpha-reductase inhibitors be at a higher risk of COVID-19 complications? [published online ahead of print, 2020 Apr 22]. Med Hypotheses. 2020; 140:109751. doi: 10.1016/j.mehy.2020.109751.
Allen S, Aghajanyan IG. Use of thermobalancing therapy in aging males with benign prostatic hyperplasia with a focus on etiology and pathophysiology, Aging Male, 2016,1-5, http://dx.doi.org/10.1080/13685538.2016.1247151.
Allen S. The Vascular Factor Plays the Main Role in the Cause of Pain in Men with Chronic Prostatitis and Chronic Pelvic Pain Syndrome: The Results of Clinical Trial on Thermobalancing Therapy. Diseases, 2017, 5(4), 25; doi:10.3390/diseases5040025.
Allen S, Aghajanyan IG. Thermobalancing conservative treatment for moderate – to - low - degree lower urinary tract symptoms (LUTS) secondary to prostate enlargement, Cogent Medicine, 2016, 3(1), 1195067. https://doi.org/10.1080/2331205X.2016.1195067.
Allen S. Personalized care using thermobalancing therapy can help men with chronic prostatitis / chronic pelvic pain syndrome to recover, Personalized Medicine Universe. 2019, 8, 48-52. doi: https://doi.org/10.1016/j.pmu.2019.04.002.
Coyne KS, Wein AJ, Tubaro A, et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety, and depression: EpiLUTS. BJU Int. 2009;103 Suppl 3:4-11. doi:10.1111/j.1464-410X.2009.08371.x.
Kwon JK, Chang IH. Pain, catastrophizing, and depression in chronic prostatitis/chronic pelvic pain syndrome. Int Neurourol J. 2013;17(2):48-58. doi:10.5213/inj.2013.17.2.48.
Zhang GX, Bai WJ, Xu T, Wang XF. A preliminary evaluation of the psychometric profiles in Chinese men with chronic prostatitis/chronic pelvic pain syndrome. Chin Med J (Engl). 2011;124(4):514-518.
Pinto JD, He HG, Chan SW, Wang W. Health-related quality of life and psychological well-being in men with benign prostatic hyperplasia: An integrative review. Jpn J Nurs Sci. 2016;13(3):309-323. doi:10.1111/jjns.12115.
Topaktaş R, Tokuç E, Ali Kutluhan M, et al. Clinical features and outcomes of COVID-19 patients with benign prostatic hyperplasia in aging males: A retrospective study of 18 cases. International Journal of Clinical Practice. 2020 June13574. DOI: 10.1111/ijcp.13574.
Allen S, Adjani A. Benign Prostatic Hyperplasia and Chronic Prostatitis Thermobalancing Therapy Can Prevent Sexual Dysfunction and Depression Linked to Medications: Importance During a Pandemic. Andrology. 2020; 9:207. doi: 10.35248/2167-0250.2020.9.207.
A. Carneiro, M.L. Wroclawski, B. Nahar, et al. Impact of the COVID-19 pandemic on the urologist’s clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period. Int Braz J Urol, 2020, 46, 4, 501-510. doi: 10.1590/S1677-5538.IBJU.2020.04.03.
Chen W, Wang XM, Fu GQ, et al. Special strategies and management of urological diseases during the COVID-19 pandemic: initial experiences from a Medical Center of China. Int Braz J Urol. 2020, 17;46(Suppl. 1): 19-25
Allen S. Thermobalancing therapy as a Self-management tool. World News of Natural Sciences, WNOFNS. 2019. Vol. 23. 84-93.
Belingheri M, Paladino ME, Riva MA. COVID-19: Health prevention and control in non-healthcare settings, Occupational Medicine, Volume 70, Issue 2, March 2020, Pages 82–83, https://doi.org/10.1093/occmed/kqaa048.
Montero-Odasso M, Goens SD, Kamkar N, et al. Canadian Geriatrics Society COVID-19 Recommendations for Older Adults. What Do Older Adults Need To Know? Can Geriatr J 2020, 23(1):149–151.
Allen S, Adjani A. Benign Prostatic Hyperplasia and Kidney Stone Disease Thermobalancing Therapy with Dr. Allen’s Device: Key to Successful Ageing Without Medications, Surgery, and Risky Exposure to Coronavirus Infection, Nephro-Urol Mon. 2021 13(2): e110771. doi: 10.5812/numonthly.110771.
